/ACB
ACB Stock - Aurora Cannabis Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$4.96-7.81%
$0.42 (-7.81%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.58
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).89
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+19.4%upside
Target: $5.92
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ACB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.91 – $5.01
TARGET (TP)$5.92
STOP LOSS$4.56
RISK/REWARD1:2.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.23
52W High$6.91
52W Low$3.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $343.29M | $270.28M | $223.80M | $221.34M | $245.25M |
| Gross Profit | $187.61M | $131.46M | $14.78M | $21.23M | $-21,558,000 |
| Gross Margin | 54.6% | 48.6% | 6.6% | 9.6% | -8.8% |
| Operating Income | $4.95M | $-46,453,000 | $-207,193,000 | $-231,449,000 | $-282,818,000 |
| Net Income | $1.59M | $-69,326,000 | $-816,627,000 | $-1,717,624,000 | $-693,625,000 |
| Net Margin | 0.5% | -25.6% | -364.9% | -776.0% | -282.8% |
| EPS | $0.03 | $-1.28 | $-8.17 | $-79.92 | $-40.92 |
Company Overview
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2024 | TD Cowen | Initiation | Buy | - |
| February 9th 2024 | Canaccord Genuity | Upgrade | Buy | - |
| September 21st 2022 | Canaccord Genuity | Upgrade | Hold | - |
| June 24th 2022 | Cantor Fitzgerald | Upgrade | Overweight | - |
| June 6th 2022 | Stifel | Upgrade | Hold | - |
Earnings History & Surprises
ACBBeat Rate
47%
Last 17 quarters
Avg Surprise
-42.9%
EPS vs Estimate
Beats / Misses
8/9
Last 12 quarters
Latest EPS
$0.09
Q4 2025
EPS Surprise History
Q1 24
-100.0%
$-0.20vs$-0.10
Q2 24
+161.1%
$0.11vs$-0.18
Q3 24
+68.6%
$-0.11vs$-0.35
Q4 24
+118.2%
$0.04vs$-0.22
Q1 25
+166.7%
$0.06vs$-0.09
Q2 25
-36.4%
$0.07vs$0.11
Q3 25
-205.6%
$-0.19vs$0.18
Q4 25
+200.0%
$0.09vs$0.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 4, 2026 | $0.20 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.03 | $0.09 | +200.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $0.18 | $-0.19 | -205.6% | ✗ MISS |
Q2 2025 | Jun 18, 2025 | $0.11 | $0.07 | -36.4% | ✗ MISS |
Q1 2025 | Feb 5, 2025 | $-0.09 | $0.06 | +166.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.22 | $0.04 | +118.2% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.35 | $-0.11 | +68.6% | ✓ BEAT |
Q2 2024 | Jun 20, 2024 | $-0.18 | $0.11 | +161.1% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $-0.10 | $-0.20 | -100.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.25 | $-0.50 | -100.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.80 | $-0.40 | +50.0% | ✓ BEAT |
Q2 2023 | Jun 14, 2023 | $-0.40 | $-1.50 | -275.0% | ✗ MISS |
Q1 2023 | Feb 9, 2023 | $-0.70 | $-1.40 | -100.0% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.90 | $-0.80 | +11.1% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-19.28 | — | — |
Q2 2022 | May 12, 2022 | $-1.60 | $-10.40 | -550.0% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $-1.70 | $-4.20 | -147.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-1.80 | $-0.90 | +50.0% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $-5.22 | — | — |
Q2 2021 | May 13, 2021 | $-1.70 | $-2.40 | -41.2% | ✗ MISS |
Latest News
Marijuana stocks sell off as Trump signs executive order to reclassify cannabis
📉 NegativeDowjones•Dec 18, 2025, 09:24 PM•Also: , ,
Cannabis stocks selling off as Trump signs rescheduling order
📉 NegativeSeeking Alpha•Dec 18, 2025, 07:21 PM•Also: , ,
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
📈 PositiveBenzinga•Dec 18, 2025, 12:21 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
📈 PositiveBenzinga•Dec 17, 2025, 01:38 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
Aurora Cannabis Launches Black Jelly, Proprietary Cultivar, Expanding Portfolio Of Medical Cannabis Products In Poland
📈 PositiveBenzinga•Dec 11, 2025, 12:13 PM
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
Aurora Cannabis, Leafio Ink Distribution Deal To Broaden Medical Cannabis Access Across Australia
📈 PositiveBenzinga•Dec 2, 2025, 12:03 PM
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
Frequently Asked Questions about ACB
What is ACB's current stock price?
Aurora Cannabis Inc. (ACB) is currently trading at $4.96 per share. The stock has moved -7.81% today.
What is the analyst price target for ACB?
The average analyst price target for ACB is $5.92, based on 1 analyst.
What sector is Aurora Cannabis Inc. in?
Aurora Cannabis Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is ACB's market cap?
Aurora Cannabis Inc. has a market capitalization of $0.28 billion, making it a small-cap company.
Does ACB pay dividends?
No, Aurora Cannabis Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRS
Aclaris Therapeutics, Inc.
$3.14
Mkt Cap: $0.3B
BIOA
BioAge Labs, Inc.
$13.39
Mkt Cap: $0.5B
CGC
Canopy Growth Corporation
$1.48
Mkt Cap: $0.4B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
HITI
High Tide Inc.
$2.77
Mkt Cap: $0.2B
IRWD
Ironwood Pharmaceuticals, Inc.
$3.13
Mkt Cap: $0.5B
LFCR
Lifecore Biomedical, Inc.
$8.04
Mkt Cap: $0.3B
LFMD
LifeMD, Inc.
$3.23
Mkt Cap: $0.2B
OGI
Organigram Global Inc.
$2.01
Mkt Cap: $0.3B
TKNO
Alpha Teknova, Inc.
$4.65
Mkt Cap: $0.2B
Explore stocks similar to ACB for comparison